StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Teva Pharma (TEVA) PT Lowered to $23 at Goldman Sachs; Remains Bullish as Expectations Reset
February 9, 2018 8:52 AM
Goldman Sachs lowered its price target on Teva Pharma (NYSE: TEVA) to ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst PT Change
Next Articles
Teva Pharma (TEVA) PT Lowered to $16.50 at Wells Fargo
February 9, 2018 8:05 AM
Teva Pharma (TEVA): OK Quarter But Headwinds Reduce PT - Deutsche Bank
February 9, 2018 7:14 AM
RBC Capital Upgrades Teva Pharma (TEVA) to Sector Perform
February 9, 2018 6:09 AM
Gabelli Downgrades Teva Pharma (TEVA) to Hold Citing FY 2018 Outlook
February 9, 2018 5:32 AM
Piper Jaffray Downgrades Teva Pharma (TEVA) to Underweight
February 9, 2018 5:04 AM
Teva Pharma (TEVA) Cut to Junk by S&P; to BB/Stable from BBB-/Watch
February 8, 2018 5:28 PM
Teva Pharma (TEVA) PT Lowered to $16 at Cowen
February 8, 2018 12:37 PM
Pre-Open Movers 02/08: (TWTR) (INFN) (GRUB) Higher; (IRBT) (GEMP) (IPHI) Lower (more...)
February 8, 2018 9:26 AM
Teva Pharma (TEVA) Leaving Room for Upside Surprise in EBITDA Guidance - Evercore ISI
February 8, 2018 8:32 AM
Teva Pharma (TEVA) Tops Q4 EPS by 17c, FY18 Guidance Falls Short of Views
February 8, 2018 7:05 AM
Teva Reports 2017 Full Year and Fourth Quarter Financial Results
February 8, 2018 7:01 AM
